Illumina, Inc.

Is Illumina, Inc. overvalued or undervalued?

As of October 31, 2025, Illumina, Inc. is considered overvalued with a valuation grade of expensive, highlighted by a P/E ratio of 26 and underperformance against the S&P 500, despite a low PEG ratio of 0.07.

As of 31 October 2025, the valuation grade for Illumina, Inc. has moved from fair to expensive, indicating that the company is currently overvalued. Key valuation ratios include a P/E ratio of 26, a Price to Book Value of 6.89, and an EV to EBITDA of 9.89, all of which suggest that the stock is trading at a premium compared to its peers. For instance, Biogen, Inc. has a P/E ratio of 13.57, highlighting a significant disparity in valuation between the two companies.<BR><BR>Furthermore, Illumina's PEG ratio stands at an exceptionally low 0.07, which typically indicates a potential undervaluation based on growth expectations; however, the overall high valuation metrics suggest otherwise. In terms of recent performance, Illumina has underperformed against the S&P 500, with a year-to-date return of -12.55% compared to the index's 16.30%. This trend of underperformance over multiple periods reinforces the conclusion that Illumina, Inc. is overvalued in its current market context.

Is Illumina, Inc. technically bullish or bearish?

As of October 31, 2025, Illumina, Inc. shows a mildly bullish technical trend despite underperforming the S&P 500, with mixed signals from indicators like the MACD and KST suggesting caution.

As of 31 October 2025, the technical trend for Illumina, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the moving averages indicate a bullish stance on the daily timeframe. Additionally, the Bollinger Bands and Dow Theory both reflect a mildly bullish outlook on both weekly and monthly timeframes. However, the KST shows a mildly bearish signal on the weekly and bearish on the monthly, which tempers the overall bullish sentiment.<BR><BR>In terms of performance, Illumina has underperformed the S&P 500 across multiple periods, with a year-to-date return of -12.55% compared to the S&P 500's 16.30%, and a one-year return of -21.97% versus the S&P 500's 19.89%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from some indicators.

How big is Illumina, Inc.?

As of Jun 18, Illumina, Inc. has a market capitalization of $17.65 billion, with net sales of $4.34 billion and a net profit of -$965 million over the last four quarters. The company's total assets are $6.30 billion, and shareholder's funds amount to $2.37 billion.

Market Cap: As of Jun 18, Illumina, Inc. has a market capitalization of 17,652.43 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Illumina reported net sales of 4,337.00 million and a net profit of -965.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 2,373.00 million, while total assets were reported at 6,303.00 million.

What does Illumina, Inc. do?

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $1.041 billion and a market cap of approximately $17.65 billion.

Overview:<BR>Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic analysis, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,041 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 131 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 17,652.43 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 26.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.35 <BR>Return on Equity: 26.59% <BR>Price to Book: 7.45 <BR><BR>Contact Details:<BR>Address: 5200 Illumina Way, SAN DIEGO CA: 92122-4616 <BR>Tel: ['1 858 2024500', '1 858 8822172'] <BR>Fax: 1 858 2024766 <BR>Website: https://www.illumina.com

Should I buy, sell or hold Illumina, Inc.?

Who are in the management team of Illumina, Inc.?

As of March 2022, the management team of Illumina, Inc. includes Executive Chairman Jay Flatley, CEO Francis deSouza, Lead Independent Director John Thompson, and Independent Directors Frances Arnold, Caroline Dorsa, Robert Epstein, and Scott Gottlieb. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Illumina, Inc. includes:<BR><BR>- Mr. Jay Flatley, who serves as the Executive Chairman of the Board.<BR>- Mr. Francis deSouza, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. John Thompson, who holds the position of Lead Independent Director.<BR>- Prof. Frances Arnold, who is an Independent Director.<BR>- Ms. Caroline Dorsa, who is also an Independent Director.<BR>- Dr. Robert Epstein, serving as an Independent Director.<BR>- Dr. Scott Gottlieb, who is an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.